Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

NCT03669718 is registered in ClinicalTrials.gov with ISA Pharmaceuticals as lead sponsor.

NCT NCT03669718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)
Lead sponsor
ISA Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2018
Completion date
June 30, 2025
Enrollment
194 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hpv16 positive, squamous cell carcinoma of the oropharynx